【正文】
l l a e t a l .( 1 9 8 8 )L o sch i a vo e ta l . ( 1 9 8 8 )HDLcholesterol (mg/dl)S t u d y b e g i nS t u d y e n d(V)LPD合并酮酸 /氨基酸補(bǔ)充 對(duì) HDL膽固醇 的作用 No of patients 63 41 20 22 19 40 nondiabetics diabetics nondiabetics nondiabetics nondiabetics nondiabetics Diet/Medication LPD/KA/EPO LPD LPD/KA/EPO/Fe VLPD/KA VLPD/KA LPD Duration (months) 36 48 12 852 418 12 Ketosteril (V)LPD合并酮酸 /氨基酸補(bǔ)充 對(duì)非傳統(tǒng)危險(xiǎn)因素的改善作用 非傳統(tǒng)危險(xiǎn)因素 飲食治療 效果 作者 高同型半胱氨酸 LPD+ KA/AA T0 vs T36 months: 45% ? Teplan et al. (2021) 血癥 (V)LPD +KA/AA LPD vs VLPD: 56% ? Bergesio et al. (2021) CRP VLPD + KA/AA T0 vs T18 months: 25% ? Di Iorio et al. (2021) LPD+ KA/AA T0 vs T36 months: 61% ? Teplan et al. (2021) (V)LPD +KA/AA LPD vs VLPD: 50% ? Bergesio et al. (2021) HPTH VLPD + KA/AA T0 vs T18 months: 45% ? Di Iorio et al. (2021) LPD+ KA/AA T0 vs T36 months: 50% ? Teplan et al. (2021) VLPD + KA/AA T0 vs T4177。 h l i n g e ta l . ( 1 9 8 3 )S ch m i cke re t a l . ( 1 9 8 7 )L i n d e n a u e ta l . ( 1 9 9 0 )C o m b e e t a l .( 1 9 9 3 )L a f a g e e t a l .( 1 9 9 2 )A p a r i ci o e ta l . ( 1 9 9 3 )B a r so t t i e ta l . ( 1 9 9 8 )D i I o r i o e t a l .( 2 0 0 3 )血清甲狀旁腺素(pg/ml)研究前研究后 患者數(shù) 46 30 22 27 17 23 21 10 持續(xù)時(shí)間(月) 6 18 12 24 12